Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 3
1994 2
1997 2
1999 1
2000 1
2001 1
2002 4
2003 3
2004 3
2005 6
2006 4
2008 6
2009 9
2010 14
2011 31
2012 23
2013 28
2014 32
2015 30
2016 15
2017 12
2018 21
2019 26
2020 39
2021 42
2022 32
2023 50
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

402 results

Results by year

Filters applied: . Clear all
Page 1
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.
Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, Albon SJ, Casanovas-Company J, Castro F, Popova B, Villanueva K, Yeung J, Vetharoy W, Guvenel A, Wawrzyniecka PA, Mekkaoui L, Cheung GW, Pinner D, Chu J, Lucchini G, Silva J, Ciocarlie O, Lazareva A, Inglott S, Gilmour KC, Ahsan G, Ferrari M, Manzoor S, Champion K, Brooks T, Lopes A, Hackshaw A, Farzaneh F, Chiesa R, Rao K, Bonney D, Samarasinghe S, Goulden N, Vora A, Veys P, Hough R, Wynn R, Pule MA, Amrolia PJ. Ghorashian S, et al. Nat Med. 2019 Sep;25(9):1408-1414. doi: 10.1038/s41591-019-0549-5. Epub 2019 Sep 2. Nat Med. 2019. PMID: 31477906 Clinical Trial.
Moreover, 40-60% of patients relapse owing to poor CAR T cell persistence or emergence of CD19(-) clones. Some factors, including the choice of single-chain spacer(6) and extracellular(7) and costimulatory domains(8), have a profound effect on CAR T cell function an …
Moreover, 40-60% of patients relapse owing to poor CAR T cell persistence or emergence of CD19(-) clones. Some factors, including the …
COVID-19 deaths on weekends.
Manzoor F, Redelmeier DA. Manzoor F, et al. BMC Public Health. 2023 Aug 22;23(1):1596. doi: 10.1186/s12889-023-16451-8. BMC Public Health. 2023. PMID: 37608262 Free PMC article.
Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia.
Alcharakh M, Yun S, Dong Y, Vincelette ND, Daud M, Manzoor S, Riaz IB, Anwer F. Alcharakh M, et al. Immunotherapy. 2016 Jul;8(8):847-52. doi: 10.2217/imt-2015-0023. Immunotherapy. 2016. PMID: 27381683 Review.
Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. ...
Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignan …
Biallelic Mutations in P4HTM Cause Syndromic Obesity.
Saeed S, Ning L, Badreddine A, Mirza MU, Boissel M, Khanam R, Manzoor J, Janjua QM, Khan WI, Toussaint B, Vaillant E, Amanzougarene S, Derhourhi M, Trant JF, Siegert AM, Lam BYH, Yeo GSH, Chabraoui L, Touzani A, Kulkarni A, Farooqi IS, Bonnefond A, Arslan M, Froguel P. Saeed S, et al. Diabetes. 2023 Sep 1;72(9):1228-1234. doi: 10.2337/db22-1017. Diabetes. 2023. PMID: 37083980
Anti-coreceptor therapy drives selective T cell egress by suppressing inflammation-dependent chemotactic cues.
Martin AJ, Clark M, Gojanovich G, Manzoor F, Miller K, Kline DE, Morillon YM, Wang B, Tisch R. Martin AJ, et al. JCI Insight. 2016 Oct 20;1(17):e87636. doi: 10.1172/jci.insight.87636. JCI Insight. 2016. PMID: 27777971 Free PMC article.
These processes were required for T cell retention, as ectopic IFN-gamma or CXCL10 inhibited Ab-mediated T cell purging. ...Coreceptor therapy therefore offers a robust approach to suppress T cell-mediated pathology by purging T cells in an inflammatio …
These processes were required for T cell retention, as ectopic IFN-gamma or CXCL10 inhibited Ab-mediated T cell purging. ...Co …
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.
Kokalaki E, Ma B, Ferrari M, Grothier T, Hazelton W, Manzoor S, Costu E, Taylor J, Bulek A, Srivastava S, Gannon I, Jha R, Gealy R, Stanczuk L, Rizou T, Robson M, El-Kholy M, Baldan V, Righi M, Sillibourne J, Thomas S, Onuoha S, Cordoba S, Pule M. Kokalaki E, et al. Mol Ther. 2023 Jul 5;31(7):2089-2104. doi: 10.1016/j.ymthe.2023.03.020. Epub 2023 Mar 21. Mol Ther. 2023. PMID: 36945773 Free article.
CAR T cells recognizing CD19 effectively treat relapsed and refractory B-ALL and DLBCL. ...
CAR T cells recognizing CD19 effectively treat relapsed and refractory B-ALL and DLBCL. ...
402 results